Lilly Neuroscience president Carole Ho (L) with Psychedelic Alpha founder Josh Hardman at the Psychedelic Healthcare Forum on Oct. 15, 2026 (Kyle LaHucik for Endpoints News)
October 16, 2026 10:04 AM EDT
Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says
Eli Lilly is interested in R&D efforts to “improve the profile of ibogaine,” the pharma giant’s neuroscience president said at a psychedelics conference Thursday.
Carole …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
ENDPOINTS CAREERS